OncoMatch/Clinical Trials/NCT06884670
Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study
Is NCT06884670 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Interleukin-2 and Tislelizumab for rectal cancer.
Treatment: Interleukin-2 · Tislelizumab · Oxaliplatin · Capecitabine — The objective is to evaluate whether the neoadjuvant combination of tislelizumab (a PD-1 inhibitor) with interleukin-2 (IL-2) chemotherapy can significantly increase the Objective Response Rate (ORR) and the Pathological Complete Response rate (pCR) in patients with locally advanced rectal cancer who have Microsatellite Stable/Proficient Mismatch Repair (MSS/pMMR) status.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Disease stage
Required: Stage ANY T WITH N+
Excluded: Stage IV
Clinical stage T3-T4 or any T with node-positive (N+) disease: locally advanced; Patients with metastatic disease (Stage IV) [excluded]
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anticancer therapy
Patients who have previously received systemic anticancer therapy for colorectal cancer
Cannot have received: anti-PD-1/PD-L1/CTLA-4 antibody
have been treated with PD-1, PD-L1, or CTLA-4 antibodies
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify